Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-402.

Armstrong MJ, Adams LA, Canbay A, et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59(3):1174-97.

Nardo AD, Schneeweiss-Gleixner M, Bakail M, et al. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 2021;41(1):20-32.

WHO. WHO COVID-19 dashboard. 2024.

Bramante C, Tignanelli CJ, Dutta N, et al. Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19. medRxiv 2020.

Younossi ZM, Stepanova M, Lam B, et al. Independent predictors of mortality among patients with NAFLD hospitalized with COVID-19 infection. Hepatol Commun. 2022;6(11):3062-72.

Forlano R, Mullish BH, Mukherjee SK, et al. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PloS One. 2020;15(10):e0240400-e.

Gao F, Zheng KI, Wang X-B, et al. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. J Gastroenterol Hepatol. 2021;36(1):204-7.

Wang G, Wu S, Wu C, et al. Association between non-alcoholic fatty liver disease with the susceptibility and outcome of COVID-19: A retrospective study. J Cell Mol Med. 2021;25(24):11212-20.

Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J. Hepatol. 2020;73(2):451-3.

Zhou YJ, Zheng KI, Wang XB, et al. Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver Int. 2020;40(9):2160-3.

Madan K, Rastogi R, Bhargava R, et al. Is fatty liver associated with increased mortality and morbidity in Coronavirus disease 2019 (COVID-19) pneumonia? J Clin Exp Hepatol. 2022;12(5):1320-7.

Nath P, Kumar R, Mallick B, et al. Effect of nonalcoholic fatty liver disease (NAFLD) on COVID-19: A single-center study of 3983 patients with review of literature. Cureus. 2022;14(7):e26683-e.

Mahamid M, Nseir W, Khoury T, et al. Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study. Eur J Gastroenterol Hepatol. 2021;33(12):1578-81.

Moctezuma-Velázquez P, Miranda-Zazueta G, Ortiz-Brizuela E, et al. NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study. Intern Emerg Med. 2022;17(5):1355-62.

Vrsaljko N, Samadan L, Viskovic K, et al. Association of nonalcoholic fatty liver disease with COVID-19 severity and pulmonary thrombosis: Covidfat, a prospective, observational cohort study. Open Forum Infect Dis. 2022;9(4):ofac073-ofac.

Yoo HW, Jin HY, Yon DK, et al. Non-alcoholic fatty liver disease and COVID-19 susceptibility and outcomes: a Korean nationwide cohort. J Korean Med Sci. 2021;36(41):e291-e.

Yuan Z, Shao Z, Ma L, et al. Clinical severity of SARS-CoV-2 variants during COVID-19 vaccination: A systematic review and meta-analysis. Viruses. 2023;15(10):1994.

Yadaw AS, Li Y-c, Bose S, et al. Clinical features of COVID-19 mortality: development and validation of a clinical prediction model. The Lancet Digital Health 2020;2(10):e516-e25.

Kaur SP, Gupta V. COVID-19 vaccine: A comprehensive status report. Virus Res. 2020;288(198114).

WHO. COVID-19 vaccination, World data [cited 2024 25 April].

Pipitone RM, Ciccioli C, Infantino G, et al. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab 2023.